Vicore Pharma Says Lung Disease Drug Helps Breathing in Covid-19 Patients

By Dominic Chopping

STOCKHOLM--Swedish pharmaceutical company Vicore Pharma Holding AB said Monday that data from a phase II study of its C21 drug suggests that, when used in conjunction with corticosteroids and remdesivir, the drug can restore lung function in Covid-19 patients.

Vicore Pharma's C21 drug is used to treat lung disease idiopathic pulmonary fibrosis.

The company said the study suggests that C21 can become an important complement to vaccines to combat the Covid-19 pandemic.

"The complete analysis confirms the initial observation that C21 is safe, restores lung function and reduces the need for oxygen supplementation in these critically ill Covid-19 patients," said Chief Executive Carl-Johan Dalsgaard.

Write to Dominic Chopping at dominic.chopping@wsj.com

(END) Dow Jones Newswires

February 01, 2021 02:34 ET (07:34 GMT)

Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024